Hans Ragnar Widlund

List of Publications by Year
in descending order

54 papers	9,606 citations	101496 36 h-index	175177 52 g-index
54 all docs	54 docs citations	54 times ranked	13986 citing authors

#	Article	IF	Citations
1	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 2005, 436, 117-122.	13.7	1,329
2	Oncogenic BRAF Regulates Oxidative Metabolism via PGC1Î± and MITF. Cancer Cell, 2013, 23, 302-315.	7.7	689
3	Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability. Cell, 2002, 109, 707-718.	13.5	671
4	BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. Current Biology, 2005, 15, 249-254.	1.8	626
5	PGC1Î± Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress. Cancer Cell, 2013, 23, 287-301.	7.7	600
6	Central Role of p53 in the Suntan Response and Pathologic Hyperpigmentation. Cell, 2007, 128, 853-864.	13.5	552
7	A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells. Cancer Cell, 2011, 20, 620-634.	7.7	449
8	Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell, 2004, 6, 565-576.	7.7	373
9	Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene, 2003, 22, 3035-3041.	2.6	337
10	GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature, 2009, 459, 1085-1090.	13.7	311
11	Î²-Cateninâ€“induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. Journal of Cell Biology, 2002, 158, 1079-1087.	2.3	268
12	MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma. American Journal of Pathology, 2003, 163, 333-343.	1.9	266
13	Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development (Cambridge), 2004, 131, 217-228.	1.2	193
14	Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma. Cancer Research, 2004, 64, 509-516.	0.4	191
15	PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E699-708.	3.3	190
16	Identification and characterization of genomic nucleosome-positioning sequences. Journal of Molecular Biology, 1997, 267, 807-817.	2.0	180
17	NFATc2-Mediated Repression of Cyclin-Dependent Kinase 4 Expression. Molecular Cell, 2002, 10, 1071-1081.	4.5	176
18	Oncogenic MITF dysregulation in clear cell sarcoma: Defining the MiT family of human cancers. Cancer Cell, 2006, 9, 473-484.	7.7	172

#	Article	IF	Citations
19	A PGC1Î±-mediated transcriptional axis suppresses melanoma metastasis. Nature, 2016, 537, 422-426.	13.7	161
20	VEGFR-1 Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor Growth. Cancer Research, 2011, 71, 1474-1485.	0.4	142
21	Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma. Clinical Cancer Research, 2008, 14, 7726-7732.	3.2	126
22	MC1R Is a Potent Regulator of PTEN after UV Exposure in Melanocytes. Molecular Cell, 2013, 51, 409-422.	4.5	122
23	An Oncogenic Role for <i>ETV1</i> in Melanoma. Cancer Research, 2010, 70, 2075-2084.	0.4	107
24	Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell and Melanoma Research, 2008, 21, 457-463.	1.5	104
25	Hypoxia-induced transcriptional repression of the melanoma-associated oncogene <i>MITF</i>. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E924-33.	3.3	101
26	Phosphatase-Dependent and -Independent Functions of Shp2 in Neural Crest Cells Underlie LEOPARD Syndrome Pathogenesis. Developmental Cell, 2010, 18, 750-762.	3.1	96
27	ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition. Cell Reports, 2017, 18, 1543-1557.	2.9	95
28	SOX2 contributes to melanoma cell invasion. Laboratory Investigation, 2012, 92, 362-370.	1.7	85
29	PGC-1 Coactivators: Shepherding the Mitochondrial Biogenesis of Tumors. Trends in Cancer, 2016, 2, 619-631.	3.8	84
30	A Tissue-restricted cAMP Transcriptional Response. Journal of Biological Chemistry, 2003, 278, 45224-45230.	1.6	83
31	Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation. Clinical Cancer Research, 2014, 20, 2257-2263.	3.2	79
32	TGGA repeats impair nucleosome formation. Journal of Molecular Biology, 1998, 281, 253-260.	2.0	76
33	Nucleosome Structural Features and Intrinsic Properties of the TATAAACGCC Repeat Sequence. Journal of Biological Chemistry, 1999, 274, 31847-31852.	1.6	72
34	DNA Sequence-Dependent Contributions of Core Histone Tails to Nucleosome Stability:â€‰ Differential Effects of Acetylation and Proteolytic Tail Removal. Biochemistry, 2000, 39, 3835-3841.	1.2	63
35	MAPK/ERK-Dependent Translation Factor Hyperactivation and Dysregulated Laminin Î³2 Expression in Oral Dysplasia and Squamous Cell Carcinoma. American Journal of Pathology, 2012, 180, 2462-2478.	1.9	58
36	Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation. Journal of Clinical Investigation, 2016, 127, 349-364.	3.9	49

#	Article	IF	Citations
37	Loss of GCNT2/I-branched glycans enhances melanoma growth and survival. Nature Communications, 2018, 9, 3368.	5.8	40
38	<i>PIK3CA</i> mutant tumors depend on oxoglutarate dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3434-E3443.	3.3	38
39	Human B Cell Differentiation Is Characterized by Progressive Remodeling of O-Linked Glycans. Frontiers in Immunology, 2018, 9, 2857.	2.2	37
40	Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma. Journal of the National Cancer Institute, 2012, 104, 1673-1679.	3.0	35
41	H3K27me3-mediated PGC1Î± gene silencing promotes melanoma invasion through WNT5A and YAP. Journal of Clinical Investigation, 2020, 130, 853-862.	3.9	32
42	Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential. Journal of Investigative Dermatology, 2015, 135, 1849-1862.	0.3	29
43	ERRÎ± Maintains Mitochondrial Oxidative Metabolism and Constitutes an Actionable Target in PGC1Î±-Elevated Melanomas. Molecular Cancer Research, 2017, 15, 1366-1375.	1.5	23
44	Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. Developmental Biology, 2006, 292, 152-164.	0.9	19
45	A Novel Role for Microphthalmia-Associated Transcription Factorâ€"Regulated Pigment Epithelium-Derived Factor during Melanoma Progression. American Journal of Pathology, 2015, 185, 252-265.	1.9	17
46	MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61. Oncogene, 2021, 40, 112-126.	2.6	14
47	IL1Î± Antagonizes IL1Î² and Promotes Adaptive Immune Rejection of Malignant Tumors. Cancer Immunology Research, 2020, 8, 660-671.	1.6	13
48	Small Interfering RNA. Journal of Investigative Dermatology, 2013, 133, 1-4.	0.3	11
49	RSK Activation of Translation Factor eIF4B Drives Abnormal Increases of Laminin Î³2 and MYC Protein during Neoplastic Progression to Squamous Cell Carcinoma. PLoS ONE, 2013, 8, e78979.	1.1	11
50	Breaking BRAF(V600E)â€"drug resistance by stressing mitochondria. Pigment Cell and Melanoma Research, 2016, 29, 401-403.	1.5	5
51	Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis. Pigment Cell & Melanoma Research, 2007, 20, 070811024453003-???.	4.0	3
52	CXCR4 pathway associated with family history of melanoma. Cancer Causes and Control, 2014, 25, 125-132.	0.8	3
53	Response to Slominski etÂ al.. Pigment Cell & Melanoma Research, 2007, 20, 309-310.	4.0	0
54	Skin Inflammation in Human Health and Disease: 2018 International Conference. Journal of Investigative Dermatology, 2019, 139, 991-994.	0.3	0